188 related articles for article (PubMed ID: 22911222)
1. Androgen deprivation induces senescence characteristics in prostate cancer cells in vitro and in vivo.
Ewald JA; Desotelle JA; Church DR; Yang B; Huang W; Laurila TA; Jarrard DF
Prostate; 2013 Mar; 73(4):337-45. PubMed ID: 22911222
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
3. [Down-regulated PTTG1 expression promotes the senescence of human prostate cancer LNCaP-AI].
Wei YY; Song XM; Xiong ZH; Lu KQ; Zheng L; Cao XL
Zhonghua Nan Ke Xue; 2019 Mar; 25(3):216-222. PubMed ID: 32216239
[TBL] [Abstract][Full Text] [Related]
4. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells.
Barakat DJ; Zhang J; Barberi T; Denmeade SR; Friedman AD; Paz-Priel I
Oncogene; 2015 Nov; 34(48):5912-22. PubMed ID: 25772238
[TBL] [Abstract][Full Text] [Related]
5. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of AGR2 induces cellular senescence in prostate cancer cells.
Hu Z; Gu Y; Han B; Zhang J; Li Z; Tian K; Young CY; Yuan H
Carcinogenesis; 2012 Jun; 33(6):1178-86. PubMed ID: 22467239
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence.
Wagner J; Damaschke N; Yang B; Truong M; Guenther C; McCormick J; Huang W; Jarrard D
PLoS One; 2015; 10(4):e0124366. PubMed ID: 25876105
[TBL] [Abstract][Full Text] [Related]
8. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
[TBL] [Abstract][Full Text] [Related]
9. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.
Echchgadda I; Chang TH; Sabbah A; Bakri I; Ikeno Y; Hubbard GB; Chatterjee B; Bose S
BMC Cancer; 2011 Jan; 11():43. PubMed ID: 21276246
[TBL] [Abstract][Full Text] [Related]
11. PKA knockdown enhances cell killing in response to radiation and androgen deprivation.
Hensley HH; Hannoun-Levi JM; Hachem P; Mu Z; Stoyanova R; Khor LY; Agrawal S; Pollack A
Int J Cancer; 2011 Feb; 128(4):962-73. PubMed ID: 20960462
[TBL] [Abstract][Full Text] [Related]
12. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
13. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
14. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.
Kaseb AO; Chinnakannu K; Chen D; Sivanandam A; Tejwani S; Menon M; Dou QP; Reddy GP
Cancer Res; 2007 Aug; 67(16):7782-8. PubMed ID: 17699783
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
Nadiminty N; Chun JY; Lou W; Lin X; Gao AC
Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579
[TBL] [Abstract][Full Text] [Related]
18. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2.
Pernicová Z; Slabáková E; Kharaishvili G; Bouchal J; Král M; Kunická Z; Machala M; Kozubík A; Souček K
Neoplasia; 2011 Jun; 13(6):526-36. PubMed ID: 21677876
[TBL] [Abstract][Full Text] [Related]
19. Argentatin B Inhibits Proliferation of Prostate and Colon Cancer Cells by Inducing Cell Senescence.
Alcántara-Flores E; Brechú-Franco AE; García-López P; Rocha-Zavaleta L; López-Marure R; Martínez-Vázquez M
Molecules; 2015 Nov; 20(12):21125-37. PubMed ID: 26633316
[TBL] [Abstract][Full Text] [Related]
20. Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.
Blute ML; Damaschke N; Wagner J; Yang B; Gleave M; Fazli L; Shi F; Abel EJ; Downs TM; Huang W; Jarrard DF
PLoS One; 2017; 12(2):e0172048. PubMed ID: 28234906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]